Information Provided By:
Fly News Breaks for February 26, 2020
JAZZ
Feb 26, 2020 | 07:49 EDT
Cowen analyst Ken Cacciatore lowered his price target on Jazz Pharmaceuticals to $165 from $200 following Q4 results. The analyst noted the Street was clearly not impressed by its smaller transactions since they don't provide clarity on the company will make p for the massive hole in the P&L if the Xyrem low-sodium strategy does not meaningfully protect that franchise. He believes the current valuation accurately reflects investor skepticism and frustration. Cacciatore maintained his Outperform rating on Jazz Pharmaceuticals shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.